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Abstract
Personality disorders (PD) are common and burdensome mental disorders. The treatment of individuals with PD
represents one of the more challenging areas in the field of mental health and health care providers need evidence-
based recommendations to best support patients with PDs. Clinical guidelines serve this purpose and are formulated by
expert consensus and/or systematic reviews of the current evidence. In this review, European guidelines for the treatment
of PDs are summarized and evaluated. To date, eight countries in Europe have developed and published guidelines that
differ in quality with regard to recency and completeness, transparency of methods, combination of expert knowledge
with empirical data, and patient/service user involvement. Five of the guidelines are about Borderline personality disorder
(BPD), one is about antisocial personality disorder and three concern PD in general. After evaluating the methodological
quality of the nine European guidelines from eight countries, results in the domains of diagnosis, psychotherapy and
pharmacological treatment of PD are discussed. Our comparison of guidelines reveals important contradictions between
recommendations in relation to diagnosis, length and setting of treatment, as well as the use of pharmacological
treatment. All the guidelines recommend psychotherapy as the treatment of first choice. Future guidelines should
rigorously follow internationally accepted methodology and should more systematically include the views of
patients and users.
Keywords: Guidelines, Personality disorders, Recommendations
Introduction
Individuals with PD often suffer extreme distress and so-
cial impairment. Compared to those without a PD, they
lead shorter lives, and their quality of life is often signifi-
cantly reduced [1, 2]. Treatment providers for patients
with PDs face a difficult task and need guidance from ro-
bust evidence in order to meet these challenges. Thus,
across the world, health authorities have independently
developed clinical guidelines for management of people
with PDs. Clinical guidelines are systematically developed
expert statements to assist practitioner and patient deci-
sions regarding appropriate healthcare for specific clinical
circumstances [3]. The first systematically developed
European guidelines on the management of PDs were
published in 2008 and 2009 and came from Finland,
Germany, the Netherlands and the UK. Furthermore, a
widening gap between healthcare costs and increasing
public demand for high-quality services has stimulated
interest on the need for robust guidelines in order to guide
more efficient targeting of resources [4, 5]. Although costs
are contextually determined to some extent, it does seem
that there are some similarities in health systems and costs
across European countries, and one can therefore argue
that a European perspective on the treatment of PDs
might exist and that this should be reflected in the guide-
lines as well.
Guidelines vary in methodological approach and quality,
and most guidelines differentiate between evidence and
practice-based recommendations. Guideline quality can be
assessed and quantified using the AGREE system (Appraisal
of Guidelines, Research and Evaluation), where a guideline
is assessed across six domains [6]. See Table 1 for domains.
An important issue when developing guidelines is how to
arrive at recommendations based on a systematic method.
The Grade working group (www.gradeworkinggroup.org)
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provides guidance on how to link the body of evidence with
the degree of strength of the recommendation (strong vs.
weak/conditional). GRADE emphasizes the importance of
phrasing recommendations using active language and of
avoiding ambiguous or unclear wording, such as ‘if clinic-
ally appropriate’ or ‘if necessary’ [7]. Guidelines using spe-
cific and active language have been shown to lead to
greater adherence than guidelines using vague or nonspe-
cific phrasing [8]. Thus, it can be a fine balance for guide-
line developers not to go beyond the evidence and yet still
provide guidance that is sufficiently specific, practical and
clinically useful.
In this paper we provide an overview of the European
guidelines that we are aware of and highlight key recom-
mendations for improvement. For each guideline we
considered the AGREE domains and especially the
rigour in the development and applicability of the guide-
lines. In reviewing the guidelines, ultimately our aim was
to identify areas of convergence as well as divergence
with a view to assisting the refinement of future itera-
tions of guidelines.
Organizational background of European guidelines
We first provide a general overview of identified guide-
lines based on geographical location and with emphasis
on organizational background, rigour of development
and perceived applicability.
Northern Europe
The earliest European guidelines that we were able to
identify derived from The Swedish Psychiatric Society.
The Society developed Clinical guidelines for personality
disorders in 2006, which were recently updated (2017) [9].
Rigour of development
The current, revised clinical guidelines were developed
based on existing research evidence. They do not include
a method section outlining a systematic evaluation of
the empirical support underlying different recommenda-
tions, but rather rely heavily on guidelines from other
countries, e.g., The National Institute for Health and
Care Excellence [10] and the Australian Clinical Practice
Guidelines [11]. On the other hand, strengths and short-
comings in current evidence, as well as topics for further
research, are integrated aspects of the clinically-oriented
discussion of care. From an evidence-based guidelines
perspective, the main limitation concerns the rigour of
development, more specifically that the path from evi-
dence to recommendation is not always transparent and
reproducible.
Applicability
the goal of the Swedish guidelines appears to have been
to develop guidelines with a ‘clinical foundation’, focusing
on the daily work with patients and their families. The
guideline takes into account a range of clinical issues re-
garding the evaluation and treatment of patients with PDs
at different levels of healthcare. It discusses dynamics and
requirements at an organizational level as well as the need
for interventions and care at the community level, includ-
ing work support.
The Finnish Current Care Guidelines for BPD were
developed by the Finnish Medical Society Duodecim in
cooperation with the Finnish Psychiatric Association in
2015 [12]. This is the second version of the guidelines.
Rigour of development
The Finnish Medical Society Duodecim is one of the
founding members of the Guidelines International Net-
work (G-I-N), so the BPD guideline has been assessed
according to the G-I-N guideline standards [13]. Work-
ing groups consisted of leading volunteer healthcare pro-
fessionals as ‘content experts’ and Current Care editors
as ‘method experts’. Before final edits and publishing,
the guidelines were sent to relevant interest groups, in-
cluding patient representatives, for comments. System-
atic method and evidence reviews were applied in the
development process, but the guideline recommenda-
tions can only partly be traced back to the supporting
evidence.
Table 1 Domains in AGREE II
Domain Main content
Scope and purpose Objectives, population and clinical questions have been clearly described.
Stakeholder involvement The guideline development group includes all relevant professional groups, and patients’
views and preferences have been included in the process.
Rigour of development Systematic search and use of evidence and link between evidence and recommendations.
Guideline has undergone external review prior to publication
Clarity of presentation Recommendations are specific and unambiguous and easily identified.
Applicability Potential organizational barriers (including costs) are discussed, and key review criteria for monitoring
and audit are provided.
Editorial independence The editorial process is independent from the funding body, and any conflicts of interests are disclosed.
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Applicability
The guidelines are intended to be used by physicians and
healthcare professionals, and therefore focus on questions
relating to diagnosis, psychotherapy in general and are
somewhat more specific with regard to medication. They
are made publicly available (http://www.kaypahoito.fi/
web/kh/suositukset/suositus?id=hoi50064), and patient
versions are available for use by the public.
In Denmark, the National Health Authority published
guidelines for BPD in 2016 [14].
Rigour of development
The working group consisted of members from several
professional associations and of method consultants from
the National Health Authority. In addition, the working
group was overseen by a reference group consisting of ex-
perts, consumers and individuals in senior management
positions. The GRADE system was used in developing the
recommendations. The working process, methods and
analyses behind the recommendations are publicly avail-
able on the National Health Authority website (https://
www.sst.dk/da/udgivelser/2015/nkr-borderline), and in-
clude an English quick-guide translation.
Applicability
Ten specific questions with regards to screening in pri-
mary care, diagnosis, length of treatment, uni- or multi-
modality treatment, monitoring outcomes and
pharmacological treatment formed the starting point for
the development of the guideline. The guidelines have
been criticised for lack of applicability by clinicians and
administrators e.g. how is it helpful or practical to know
that there is not robust evidence for differences in out-
comes between short vs. long treatments? The Danish
guidelines are currently in the process of being updated.
Currently, there are no Norwegian national clinical
guidelines for PDs. The Norwegian National Advisory
Unit on Personality Psychiatry (NAPP) has recently sent
an inquiry to the Norwegian health authorities recom-
mending the development of national clinical guidelines
to stimulate the establishment of treatment programmes,
sound evaluation practices and adequate referral criteria
to various levels of the healthcare system.
Western Europe
In Germany, the AWMF (Arbeitsgemeinschaft der
Wissenschaftlichen Medizinischen Fachgesellschaften, in
English: The Association of the Scientific Medical Soci-
eties in Germany) is responsible for the development of
guidelines by the scientific medical societies.
Rigour of development
Treatment guidelines for PD were first developed in
2009 by a committee of experts as delegated by a variety
of professional societies and associations [15]. A system-
atic search for evidence was conducted, and the body of
evidence is well described. The AWMF distinguishes be-
tween different levels of guidelines based on their level
of evidence and quality, from S1 (experts’ recommenda-
tions) to S3 (systematic and evidence-based) [16]. The
first guideline was at level S2. Currently, an S3 guideline
on BPD is in progress, and strong emphasis has been
placed on maximum transparency and applicability in
addition to systematic integration of both evidence and
consensus.
Applicability
Due to the lack of efficacy studies, with the exception of
BPD, recommendations in the 2009 guideline for the
treatment of PD subtypes are based primarily on clinical
expertise or published expert opinions. This is a major
limitation as guidelines based on consensus are likely to
have limited impact.
In the Netherlands, the first Multidisciplinary Guide-
line for PD was published in 2008 [17].
Rigour of development
The guideline was developed by an expert workgroup
and is based on the results of scientific research critically
and systematically appraised according to the level of
evidence and completed with professional expertise.
However, the connection between evidence and strength
of recommendations is not fully transparent and many
recommendations were based on very low levels of
evidence.
Applicability
The guideline was developed to improve the treatment
of individuals with PDs. Questions concerning the role
of the patient and the family, diagnosis, therapeutic in-
terventions, nursing care, vocational therapies, pharma-
cological interventions, co-morbidity, cost effectiveness
and organization of care, guided the discussions of a
Working Group that was responsible for the result. The
major limitation of the guideline concerned implementa-
tion, especially in regard to systematically considering
barriers and monitoring progress. Furthermore, the
guideline has been criticized for being too focused on
patients receiving specialist psychotherapy and neglectful
of other types of care e.g. psychiatric management and
vocational therapy. This perspective has now been cov-
ered in a standardized procedure of care for patients
with BPD published in 2017 [18]. This Standard of Care
was developed and formulated from the patient’s per-
spective and the main goal of care was psychosocial
recovery.
In the United Kingdom, National Institute of Health
Care and Excellence (NICE) is an independent public
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body that provides national guidance and advice to im-
prove health and social care in the United Kingdom
(https://www.nice.org.uk/). NICE commissions the Na-
tional Collaborating Centre for Mental Health to set up
working groups to develop guidelines. In 2009, the
Guidelines on BPD [10] and Antisocial Personality dis-
order [19] were published.
Rigour of development
The guidelines cover many clinically important ques-
tions, but recommendations are often based on clinical/
expert consensus rather than evidence. The emergence
of new evidence has been monitored since 2009, but
none of the emergent evidence has been deemed suffi-
ciently strong to warrant changing the guideline
recommendations.
Applicability
Despite criticism of some of the recommendations [20],
the guidelines have been highly influential. Because of
the proficiency in English by most academics across Eur-
ope, these guidelines have been used and referenced in
all later European guidelines, and according to Google
Scholar, the two guidelines have thus far been cited
more than 250 times in the scientific literature.
In Switzerland, the Swiss Association for Psychiatry
and Psychotherapy set up a task force consisting of per-
sonality experts with the aim of coming up with prac-
tical and relevant clinical treatment recommendations
for BPD rather than a new guideline. The task force
published recommendations in 2018 (https://www.psyc
hiatrie.ch/sspp/specialistes-et-commissions/recommanda
tions-therapeutiques) [21]. The recommendations are
currently available in French and German.
Rigour of development
The guideline has several strengths in addressing im-
portant clinical questions and in considering national
particularities but may be criticised in terms of a lack of
transparency in using multiple levels of evidence without
defining how this is reflected in the strength of
recommendations.
Applicability
Recommendations were based on a consensus view giv-
ing weight to scientific evidence, good clinical practice
and national applicability. However, a lack of diverse
representation in the guideline development group may
have limited the utility of these recommendations.
Southern Europe
In Spain, a clinical practice guideline for BPD was devel-
oped in 2011 by the Catalan Agency for Health Informa-
tion, Assessment and Quality.
Rigour of development
Methodologically, the guideline was developed using the
system SIGN (Scottish Intercollegiate Guidelines Net-
work) [22]. The guideline was developed by a team in-
cluding a methodology consultant, psychiatrists,
psychologists, a nurse and social workers, and was based
on a systematic search and rating (AGREE and
OSTEBA) of evidence.
Applicability
The guideline is oriented towards specialists in mental
health who are responsible for the treatment and care of
individuals with BPD, including: psychiatrists, clinical psy-
chologists, nurses, social workers, educators, occupational
therapists, and other professionals of the NHS. Clinical
areas included in the guideline are: prevention, diagnosis
and interventions in both psychological and psycho-social
domains as well as in pharmacological treatment,
organization of services and programs for primary health
care services, community care services, hospitalization
services, partial hospitalization services / day hospital,
community rehabilitation services, continuation of care
program, and care itinerary. Issues pertaining to applic-
ability and implementation were, similarly to other guide-
lines, only addressed sparsely.
Main recommendations across guidelines
In evaluating the different guidelines, we focused on
three main areas: diagnosis, psychological treatment and
pharmacological treatment. These areas were chosen be-
cause recommendations in diagnosis and general treat-
ment should be independent of national health systems
and thus be generalizable to the whole of Europe. It is
clear that there are both similarities and discrepancies
across guidelines.
Regarding diagnoses (see Table 2), there is some con-
sensus on the use of semi-structured interviews, al-
though the Swedish guidelines specifically state that
such interviews alone are not sufficient. Instead, they
suggest adopting the LEAD principle (Longitudinal Ex-
pert All Data) as the gold standard. Screening tools are
addressed in three guidelines. The Swedish guidelines
warn against using screening for diagnostic purposes,
while the Danish guidelines go even further in not
recommending the use of screening in primary care due
to the high rate of false positives and negatives. Finally,
the Swiss guidelines recommend the use of screening in-
struments to ascertain specific symptoms and differential
diagnoses. The question of severity of the disorder is
only directly addressed in the new Swiss guidelines,
which state that it should be taken into consideration.
On a general level, the consensus regarding the diagno-
sis of PD is focused on which instruments to use and
with what purpose and caveats. Only the Swedish
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guideline recommends that while an evaluation of general
criteria can be conducted in any part of the healthcare sys-
tem, the diagnosis of a specific personality syndrome
should only be made by specialist psychiatric services. It is
not entirely clear whether this runs counter to the British
guideline, which specifies that community mental health
services should be responsible for routine assessment.
With regard to recommendations for psychological
treatment, it is noteworthy that the vast majority of evi-
dence and recommendations pertains to BPD (See
Table 3). The only recommendations we found for Anti-
social Personality Disorder were cognitive-behavioural
therapy (CBT), which was recommended by both the
British and the German guidelines. In addition, the
German guidelines state that CBT has the strongest
empirical support in the treatment of Avoidant PD
(AvPD). However, both guidelines date back to 2009,
with new relevant evidence having emerged since
then [23, 24].
For BPD, there is broad consensus that outpatient psy-
chotherapy should be the primary treatment. However,
inpatient treatment specifically adapted to BPD and day
hospital treatment are also recommended. The recom-
mendations in terms of both length of treatment and
use of multiple modalities are not clear and are some-
times contradictory even within a guideline as well as
between guidelines. For instance, the Danish guidelines
include a practice-based recommendation of both
short (< 12 months) and long-term treatments, while
the British guidelines specifically warn against the use
of psychotherapy treatments lasting less than 3
months. Also, few guidelines mention specific theoret-
ical approaches, such as Mentalization-Based Therapy
(MBT), Dialectical Behaviour Therapy (DBT),
Transference-focused Psychotherapy (TFP), or Schema
Therapy. One noteworthy exception, however, is the
German guideline, which specifically state that DBT
has better empirical evidence than other types of spe-
cialized psychotherapy for BPD. However, in a recent
meta-analysis it was concluded that both DBT and
psychodynamic approaches (the last category defined
very broadly and including both MBT and brief ther-
apy based on psychoanalytic principles) are effective
for BPD symptoms [25].
Table 2 European recommendations on PD diagnoses
Guideline population Recommendations
Swiss (2018) BPD BPD is diagnosed according to the ICD-10 (11) or DSM-5 criteria and a structured interview (e.g., SCID-II, IPDE)
is recommended for the final diagnosis.
The dimensional depiction of the psychosocial severity is gaining importance for the treatment plan and
should be taken into consideration, e.g., according to criterion A in DSM-5.
Differential diagnoses of BPD should be carefully distinguished.
Specific symptoms and differential diagnoses can be additionally ascertained with screening instruments
(e.g., questionnaires)
Swedish (2017) PD Screening tools, self-report or semi-structured diagnostic interviews are not sufficient for diagnosis.
Diagnostic evaluation should be based on the LEAD principles (Longitudinal Expert All Data).
Evaluation of general criteria for personality syndrome can be made in all parts of the health care system,
while diagnosing specific personality syndromes is a task for the psychiatric specialist services.
Danish (2016) BPD Screening tools should not be used for the identification of potential borderline personality disorder in the
primary sector on a routine basis.
It is good practice to diagnose patients with borderline personality disorder using a semi-structured clinical
personality interview.
Finnish (2015) BPD SCID-II-interview may increase the accurateness of PD diagnosis.
Catalonia (2011) BPD It is recommended as good practice to use a semi-structured clinical personality interview for the diagnosis.
Diagnosis preferably from the age of 16 to be restrictive in the diagnosis of the youngest.
Make appropriate differential diagnosis to distinguish from other disorders
German (2009) PD Patients with PD should be diagnosed using a (semi)-structured clinical interview.
For dimensional rating, disorder-specific self-assessment questionnaires are recommended.
Open communication of diagnosis is recommended
British (BPD) BPD Community mental health services should be responsible for routine assessment.
British (2009) ASPD When assessing a person with possible antisocial personality disorder, fully assess: antisocial behaviours,
personality functioning, coping strategies, strengths and vulnerabilities, comorbid mental disorders (including
depression and anxiety, drug or alcohol misuse, post-traumatic stress disorder and other personality disorders),
the need for psychological treatment, social care and support, and occupational rehabilitation or development
and domestic violence and abuse.
Use structured assessment methods whenever possible to increase the validity of the assessment. In forensic
services, use measures such as PCL-R or PCL-SV to assess the severity of antisocial personality disorder as part
of the routine assessment process.
Dutch (2008) PD The diagnosis of a personality disorder is preferably based on a combination of a clinical interview and
structured interviews.
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Finally, recommendations on pharmacological treat-
ment are in overall agreement that, based on sparse trial
evidence, medication should not be considered the pri-
mary intervention for PD, but should be used mainly for
treating comorbid disorders and in some cases used
briefly during times of crisis (see Table 4). The Swiss,
Finnish and Dutch guidelines suggest that medication
may be used to reduce specific dimensions of BPD such
as anger, impulsivity or negative mood. However, these
specific recommendations are not consistent and are
somewhat at odds with the more general recommenda-
tion of being cautious with the use of medications.
Discussion
Over the past decade, throughout Europe, a range of
clinical guidelines for the management of PDs have
emerged. The development of more rigorous guidelines
has only been possible through the exponential growth
of research data showing that PDs, particularly BPD are
treatable conditions. The publication of dismantling
studies, and the wider availability of treatment manuals
and adherence rating scales have further assisted the
process of scrutinising the process of treatment and its
efficacy. These activities should instil optimism for the
future development of high-quality mental health ser-
vices for people in need of specific PD treatments across
Europe. However, as we have shown in this brief over-
view, existing guidelines still have many limitations that
need to be effectively tackled in future iterations.
Although national variations in the context of mental
health service delivery and varying needs of the populations
could justify some variation between national guidelines,
Table 3 European recommendations on psychotherapy for Personality disorders
Guideline Pop. Recommendations
Swiss (2018) BPD The primary form of treatment is outpatient psychotherapy 1–2 sessions a week over a time span of 1–3 years.
Disorder-specific inpatient psychotherapy
(In a psychotherapeutic ward with a treatment concept adapted specifically for BPD) (Elective treatment
according to individual indication).
Swedish (2017) PD Treatment of personality syndromes may often involve multidisciplinary teams and multimodal programs.
Specialist services should be able to offer one or more of the evidence-based psychotherapies for borderline
personality disorder.
There is insufficient empirical support for choosing between short-term or long-term psychotherapies.
Danish (2016) BPD It is good practice to offer either multimodal treatment programs including psychotherapy or unimodal
psychotherapy to patients with borderline personality disorder.
It is good practice to offer either short-term psychotherapy (< 12 months) or long-term psychotherapy
(≥ 12months).
It is good practice to consider monitoring psychotherapy offered to patients with borderline personality
disorder.
Finnish (2015) BPD Some psychotherapeutic approaches can effectively relieve the symptoms and distress of patients as well
as promote adaptation and enhance functioning.
Treatment should be delivered as outpatient treatment as much as possible, and inpatient treatment should
be mostly day hospital treatment.
Catalonia (2011) BPD Recommend the use of DBT for treatment and (with less evidence) the use of MBT and Schema Focused
Therapy
German (2009) PD Four treatments are recommended as good practice: dialectic-behavioral therapy (DBT), mentalisation-based
therapy (MBT), schema therapy/ schema-focused and transference-focused therapy (TFP).
DBT treatment shows better empirical evidence than MBT, schema-focused therapy and TFP for BPD.
British (BPD) (2009) BPD When providing psychological treatment for people with borderline personality disorder, especially those with
multiple comorbidities and/or severe impairment, the following service characteristics should be in place:
- An explicit and integrated theoretical approach used by both the treatment team and the therapist,
which is shared with the service user
- Structured care in accordance with this guideline
- Provision for therapist supervision.
- Although the frequency of psychotherapy should be adapted to the person’s needs and context of living,
twice-weekly sessions may be considered.
Do not use brief psychotherapeutic interventions (of less than 3 month’s duration) specifically for borderline
personality disorder or for the individual symptoms of the disorder.
British (2009) ASPD For people with antisocial personality disorder, including those with substance misuse problems, in community
and mental health services, consider offering group-based cognitive and behavioural interventions, in order to
address problems such as impulsivity, interpersonal difficulties and antisocial behaviour.
Dutch (2008) PD Several individual ambulatory psychotherapies are effective in treating people with a personality disorder.
There is evidence that therapies that have been shown effective in treating Axis I disorders without a
personality disorder are also effective in treating people who also have a personality disorder.
There is evidence that treating people with a personality disorder with psychotherapy is cost effective
compared to treatment as usual and no therapy
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the differences we have identified are probably due to, to a
large extent, the lack of methodological rigour with which
guidelines have been developed along with the paucity of
evidence for many of the clinical questions addressed by
the guidelines. Since guidelines should base their recom-
mendations on an evidence-based paradigm, and since their
strongest recommendations stem from randomized con-
trolled trials, it would be reasonable to expect guideline au-
thors to adopt the same strict practices required when
reporting such trials (Consolidated Standards of Reporting
Trials – CONSORT) (http://www.consort-statement.org).
This would mean that guideline authors should adhere to
harmonised standards for reporting their recommendations
in a complete and transparent way. Unfortunately, cur-
rently, we are far from such practices. Although the
number of RCTs has considerably increased since the de-
velopment of the first BPD Guideline [26], the need for
further research should be stressed, as many of the current
evidence-based treatments for BPD do not yet reach the
condition of “sufficient evidence”. The particular case of
DBT compared to TAU, may be the only exception [27]. A
second limitation seen in the majority of the guidelines
reviewed, is a lack of a systematic process for capturing
the views and values of patients and carers. In order to be
relevant and useful, clinical guidelines need to provide cli-
nicians with advice that will help them make decisions
about patient care based, on the weighting and negotiation
of medical knowledge arising from more sources than ex-
perimental research. Patients’ needs, and values are im-
portant sources of such knowledge and should be solicited
Table 4 European recommendations on medication for Personality disorders
Guideline Pop. Recommendations
Swiss (2018) BPD Medication should be restricted to critical situations and administered for a short timespan
In case of need, symptom-focused hierarchical organization
- Lamotrigin and Topiramat is administered for anger, aggression and impulsivity
- Quetiapin and Aripiprazol is administered for irritability and cognitive-perceptive symptoms
Generally, dosage is kept in the lower range. Benzodiazepines should be completely avoided
Treatment of comorbidities should be evaluated systematically and thoroughly
No Polypharmacy.
Swedish (2017) PD Medication should not be offered as a primary treatment for personality syndromes but may be applied
treating co-occurring symptom disorders.
Danish (2016) BPD Antidepressants should only be used for the treatment of patients with borderline personality disorder upon
due consideration.
Mood stabilizers should only be used for the treatment of patients with borderline personality disorder upon
due consideration.
Antipsychotics should only be used for the treatment of patients with borderline personality disorder upon due
consideration
Finnish (2015) BPD Antipsychotic medication might relieve symptoms in multiple dimensions.
Mood stabilizers may be useful in reducing impulsivity and aggression. Serotonin reuptake inhibitors may be
useful especially in treatment of comorbidity.
There is a risk of polypharmacy in pharmacological treatment.
Mood stabilizers and 2nd generation antipsychotics are preferred in pharmacotherapy.
Catalonia (2011) BPD There is no evidence for any pharmacological treatment. It is recommended to avoid the use of
benzodiazepines due to the risk of abuse and dependence.
The pharmacological treatment should be considered as a coadjuvant of the psychotherapeutic or the
psychosocial intervention to globally improve or to improve one of its characteristic symptoms.
The pharmacological treatment in patients with BPD must be periodically reviewed, with the aim of eliminating
unnecessary or ineffective medications as well as avoiding polypharmacy.
German (2009) PD Pharmacological treatment can be considered for crisis-like aggravation and comorbid disorders. There is no
evidence for pharmacological treatment of PD only, it should always be combined with psychotherapy.
British (BPD) (2009) BPD Do not use:
Drug treatment specifically for borderline personality disorder or for the individual symptoms or behaviour
associated with the disorder.
Antipsychotic drugs for the medium- and long-term treatment of borderline personality disorder.
Consider drug treatment in the overall treatment of comorbid conditions.
Consider cautiously short-term use of sedative medication as part of the overall treatment plan for people with
borderline personality disorder in a crisis. Agree the duration of treatment with them, but it should be no
longer than 1 week.
Review the treatment of those who do not have a diagnosed comorbid mental or physical illness and who are
currently being prescribed drugs. Aim to reduce and stop unnecessary drug treatment.
British (2009) ASPD Pharmacological interventions should not be routinely used for the treatment of antisocial personality disorder
or associated behaviours of aggression, anger and impulsivity.
Dutch (2008) PD There is evidence that antipsychotics, SSRI’s and mood stabilizers may improve targeted symptoms of a
personality disorder and the global functioning.
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in a systematic way in the process of establishing future
clinical guidelines.
As our review clearly shows, clinical guidelines for PD
treatment focus almost exclusively on research on BPD,
although this has not always been made explicit by the
authors. There is, however, a need to distinguish general
PD guidance from BPD guidance. Naturally, there are
similarities in the broader field of recommended PD
treatment, but also important differences, for example
with respect to treatment of suicidal and self-harming
behaviours, where arguably distinctions in the guidance
for BPD and other PDs should be made [28]. A chal-
lenge to making such clear distinctions is, of course, the
widespread comorbidity often seen in people with PDs,
not only in terms of several comorbid PDs, but also in
terms of comorbidity with other clinical syndromes,
such as anxiety, depression, post-traumatic stress dis-
order and substance use disorders. People with multiple
disorders often receive too many or conflicting therapies
and solving this problem and creating a basis for person-
alized treatment is a huge challenge to future develop-
ment of clinical guidelines for PD treatment.
Little is gained if clinical guidelines are not made known
among clinicians who need them and if no measures are
taken to implement them in the field of practice. This cru-
cial aspect of promoting evidence-based practices regarding
PD treatments is seemingly neglected in existing guidelines,
as we have shown. Guidelines could include steps to be
taken to ensure that clinicians receive proper training in
empirically supported treatments including how systems of
supervision and adherence rating could be put in place to
ensure that standards are upheld over time. Guideline doc-
uments could also provide guidance on how to conduct
clinical audits in mental health service centres at regular in-
tervals as a measure to assess the need for improvements
on a larger scale. These are just some suggestions on how
implementation aspects could be addressed in future guide-
line documents. Clearly, there is a need for more research
to study the real effectiveness of such implementation mea-
sures. The implementation of empirically-based treatments
and its empirical documentation is lagging at least two de-
cades behind the development and empirical validation of
the treatments themselves [29].
The recently published DSM-5, with its Alternative
Model for PDs as well as the upcoming ICD-11, focuses a
great deal on severity in the diagnosis of PDs. With the not-
able exception of the recent Swiss guideline, none of the
guidelines address the issue of severity. There are empirical
data showing that more severely disturbed patients might
need longer treatments to improve [30], as well as
population-based data showing that severity of PD is ro-
bustly associated with future risk of poor health and rela-
tionship difficulties [31] . Furthermore, a clinically derived
stepwise model on how to apply different and more intense
treatments for BPD patients with increasing severity has re-
cently been published by [32]. In light of prominence in
both ICD-11 and DSM-5, we think the issue of severity will
have to be considered in future iterations of guidelines.
Although we found a considerable overlap between the
different national guidelines, there were also significant dif-
ferences. These may in part reflect the different ages of the
guidelines. In addition, different domains of outcome are
now looked at more thoroughly today than they were in
the past and it is acknowledged that a treatment that is ef-
fective in one domain does not necessarily confer effective
treatment in another domain [26]. Another discrepancy in
the guidelines´ recommendations can be found regarding
medication. While for example, some guidelines recom-
mend the prescription of antipsychotic or antidepressant
medication to target specific symptoms, other guidelines in-
sist on a general caution when it comes to psychopharma-
cological treatment. Whilst there is no current evidence
that any form of medication can modify the enduring fea-
tures of personality, there is some evidence for positive ef-
fects of medication in the domains of mood stabilization
and impulsivity [33]. As a consequence, future guidelines
should – as mentioned above – clarify the rationale of their
recommendations in terms of the target domains of differ-
ent treatments.
Finally, the expiry date of guidelines warrants consider-
ation. We think in view of the rapidly growing number of
empirical studies in the field, the relevance and complete-
ness of BPD guidelines should be reviewed at least every
5 years. Following outdated guideline recommendations
might not reflect empirically-based treatment, but rather
the opposite. Thus, we strongly support the practice of the
German Association of the Scientific Medical Societies,
that remove a guideline from its website five years after
publication unless it is updated according to a defined
procedure. For PDs in general a five years criterion might
be too strict due to the slower accumulation of evidence.
As a final methodological consideration of this over-
view of European guidelines we acknowledge that use of
the AGREE system would have been a more systematic
approach for guideline quality appraisal. However, the
AGREE manual [6] recommends at least 2 appraisers
and preferably 4 in order to achieve a reliable rating and
due to language barriers and the unfunded nature of the
project this was not considered feasible.
Conclusions
We conclude that a) a more systematic approach of captur-
ing the views and values of patients and carers is needed in
the process of developing new guidelines; this will help
make the guidelines more clinically relevant and have
greater utility of clinicians and patients alike, b) since guide-
lines have so far focused almost exclusively on BPD and
guidelines for other PDs are either outdated or missing
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completely, there is a strong need for future guidelines to
include these other PDs, c) future guidelines need to have a
stronger focus on how their recommendations will be
audited and brought into practice and, finally d) the issue
of severity is generally neglected in existing guidelines,
hence there is a need for future guidelines to take this di-
mension into consideration and align with the forthcoming
ICD-11. Collaboration between researchers working across
Europe is needed to speed up this important development
work and, in this respect, the ESSPD provides a helpful
platform for dialogue and development on this topic and
will support initiatives directly aimed at strengthening fu-
ture collaboration on PD guidelines across Europe.
Acknowledgements
The authors thank Ad Kaasenbrood, M.D., PhD and Sebastian Euler, M.D. for
providing valuable assistance with evaluating the Dutch and Swiss
guidelines, respectively.
Funding
Not applicable.
Availability of data and materials
Not applicable.
Authors’ contributions
SS drafted the introduction, the section about main recommendations and
the conclusions. TW and AK wrote the section about North European
guidelines. BR and SS wrote the section about Western European guidelines
and JSR wrote the section about the guideline from Southern Europe. SD,
LM and ST wrote the discussion. All authors commented on drafts and
approved the final version.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
SS, AB, MB, SD, JSR and LM are either presently involved or have previously
been involved in randomized controlled trial of MBT, DBT and TFP. SS was
part of the workgroup for the Danish guidelines. AB and PAM were part of
the workgroup for the British guidelines. MB, BR and ST have either
previously or are presently involved in development of the German
guidelines.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Stolpegaard Psychotherapy Centre, Copenhagen, Denmark. 2University
College, London and Anna Freud National Centre for Children and Families,
University of Copenhagen, London, UK. 3Institute of Psychiatric and
Psychosomatic Psychotherapy; Central Institute of Mental Health, Heidelberg
University, Mannheim, Germany. 4Private practice, Weesp, The Netherlands.
5Department of Psychoanalysis and Psychotherapy, Medical University of
Vienna, Vienna, Austria. 6Kanta-Häme Central Hospital, Hämeenlinna, Finland.
7Centre for Academic Mental Health, Department of Population Health
Sciences, Bristol Medical School, University of Bristol, Bristol, UK. 8Freie
Universität, Berlin, Germany. 9Department of Psychiatry, Hospital de la Santa
Creu i Sant Pau, Barcelona, Spain. 10Centro de Investigación Biomédica en
Red de Salud Mental, CIBERSAM, Madrid, Spain. 11Universitätsklinikum
Heidelberg | Universität Heidelberg, Heidelberg, Germany. 12Department of
Research and Development, Division of Mental Health and Addiction, Oslo
University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo,
Norway. 13National Centre for Suicide Research and Prevention, Institute of
Clinical Medicine, University of Oslo, Oslo, Norway.
Received: 11 March 2019 Accepted: 30 April 2019
References
1. Fok ML-Y, et al. Life expectancy at birth and all-cause mortality among
people with personality disorder. J Psychosom Res. 2012;73(2):104–7.
2. Cramer V, Torgersen S, Kringlen E. Personality disorders and quality of life. A
population study. Compr Psychiatry. 2006;47(3):178–84.
3. Field M, Lohr K. Institute of Medicine Committee to advise the public
Health service on clinical practice guidelines. In: Clinical practice guidelines:
directions for a new program. Washington, DC: National Academy Press;
1990.
4. Woolf SH, et al. Potential benefits, limitations, and harms of clinical
guidelines. Bmj. 1999;318(7182):527–30.
5. Woolf S, et al. Developing clinical practice guidelines: types of evidence and
outcomes; values and economics, synthesis, grading, and presentation and
deriving recommendations. Implement Sci. 2012;7(1):61.
6. Brouwers MC, et al. AGREE II: advancing guideline development, reporting
and evaluation in health care. Can Med Assoc J. 2010;182(18):E839–42.
7. McDonald CJ, Overhage JM. Guidelines you can follow and can trust: an
ideal and an example. Jama. 1994;271(11):872–3.
8. Grol R, et al. Attributes of clinical guidelines that influence use of guidelines
in general practice: observational study. Bmj. 1998;317(7162):858–61.
9. Ekselius L, et al. Personlighetssyndrom, kiniska riktlinjer för utredning och
behandling. 2017: Gothia Förlag AB.
10. Excellence, N.I.f.H.a.C., Borderline personality disorder: treatment and
management (CG78). 2009.
11. Health, N. and M.R. Council, Clinical practice guideline for the management
of borderline personality disorder. 2012, National Health and Medical
Research Council Melbourne.
12. Association, F.M.S.D.a.t.F.P., Epävakaa persoonallisuus. Käypä hoito -suositus.
[Borderline Personality Disorder. Current Care Guidelines]. 2015.
13. Qaseem A, et al. Guidelines international Network: toward international
standards for clinical practice guidelines. Ann Intern Med. 2012;156(7):525–31.
14. Vind, AB, et al. National klinisk retningslinje for behandling af emotionel
ustabil personlighedsstruktur, borderline type. 2015.
15. DGPPN - Deutsche Gesellschaft für Psychiatrie, P.u.N.H., Behandlungsleitlinie
Persönlichkeitsstörungen. Reihe: S2 Praxisleitlinien in Psychiatrie und
Psychotherapie, Band 1. 2009.
16. Muche-Borowski C, et al. Das AWMF-Regelwerk Leitlinien: Ständige
Kommission “Leitlinien” der Arbeitsgemeinschaft der Wissenschaftlichen
Medizinischen Fachgesellschaften (AWMF). 2012.
17. Committee DPMG. Dutch multidisciplinary guideline for personality
disorders. Utrecht: Trimbos-institute; 2008.
18. Instituut, T, Zorgstandaard persoonlijkheidsstoornissen:
Kwaliteitsontwikkeling GGZ [Care standard personality disorders: Quality
development mental health care]. 2017.
19. Excellence, N.I.f.H.a.C., Antisocial personality disorder:prevention and
management (Clinica guideline CG77). 2009.
20. Omar H, Tejerina-Arreal M, Crawford MJ. Are recommendations for
psychological treatment of borderline personality disorder in current UK
guidelines justified? Systematic review and subgroup analysis. Personal
Ment Health. 2014;8(3):228–37.
21. Euler S, et al. Borderline-Störung: Behandlungsempfehlungen der SGPP.
Psychiatr Psychother. 2018;169(5):135–43.
22. Network, S.I.G., R.T. Harbour, and L. Forsyth, SIGN 50: a guideline developer's
handbook. 2008: Scottish Intercollegiate Guidelines Network.
23. Bamelis LL, et al. Results of a multicenter randomized controlled trial of the
clinical effectiveness of schema therapy for personality disorders. Am J
Psychiatr. 2014;171(3):305–22.
24. Weinbrecht A, et al. Avoidant personality disorder: a current review. Curr
Psychiatry Rep. 2016;18(3):29.
25. Cristea IA, et al. Efficacy of psychotherapies for borderline personality disorder:
a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(4):319–28.
26. Association, A.P., Practice guideline for the treatment of patients with
borderline personality disorder. 2001: American Psychiatric Pub.
27. Stoffers-Winterling JM, et al. Psychological therapies for people with
borderline personality disorder. Cochrane Database Syst Rev. 2012(8):1-255.
Simonsen et al. Borderline Personality Disorder and Emotion Dysregulation             (2019) 6:9 Page 9 of 10
28. Mehlum L. DBT as a Suicide and Self-harm Treatment: Assessing and
Treating Suicidal Behaviours. The Oxford handbook of dialectical behaviour
therapy. Oxford: Oxford University Press; 2018.
29. McHugh RK, Barlow DH. The dissemination and implementation of
evidence-based psychological treatments: a review of current efforts. Am
Psychol. 2010;65(2):73.
30. Tmej A, et al. Changes in attachment representation in psychotherapy: is
reflective functioning the crucial factor? Z Psychosom Med Psychother.
2018;64(3):222–36.
31. Moran P, et al. The influence of personality disorder on the future mental
health and social adjustment of young adults: a population-based,
longitudinal cohort study. Lancet Psychiatry. 2016;3(7):636–45.
32. Choi-Kain LW, Albert EB, Gunderson JG. Evidence-based treatments for
borderline personality disorder: implementation, integration, and stepped
care. Harvard Review of Psychiatry. 2016;24(5):342–56.
33. Stoffers J, et al. Pharmacological interventions for borderline personality
disorder. Cochrane Database Syst Rev, 2010(6):1-324.
Simonsen et al. Borderline Personality Disorder and Emotion Dysregulation             (2019) 6:9 Page 10 of 10
